Table 2 Ongoing and completed clinical trials involving the combination of DC vaccines and ICBs.
NCT Number | Conditions | Phase | Interventions | Status |
|---|---|---|---|---|
NCT02529072 | Recurrent Grade III and Grade IV Brain Tumors | Phase â… | DC vaccine + Nivolumab | Completed |
NCT03092453 | Melanoma | Phase â… | DC vaccine + Pembrolizumab | Completed |
NCT03035331 | NHL | Phase â… /â…¡ | DC therapy + cryosurgery + Pembrolizumab | Completed |
NCT03879512 | Childhood Glioblastoma | Phase â… /â…¡ | DC vaccine + metronomic cyclophosphamide + Nivolumab + Ipilimumab | Completed |
NCT03325101 | Metastatic or Unresectable Melanoma | Phase â… /â…¡ | DC therapy + cryosurgery + Pembrolizumab | Completed |
NCT01302496 | Stage III or IV Malignant Melanoma | Phase â…¡ | TriMix-DC + Ipilimumab | Completed |
NCT01804465 | Prostate Cancer | Phase â…¡ | Sipuleucel-T + Ipilimumab | Completed |
NCT02677155 | Follicular Lymphoma | Phase â…¡ | DC vaccine + Pembrolizumab + Rituximab + Radiotherapy | Completed |
NCT06329908 | Advanced Lung Cancer Resistant to ICIs | Early Phase â… | DC vaccine + ICIs | Recruiting |
NCT05631886 | Local Advanced/Metastatic Solid Tumors or R/R Lymphomas | Phase â… | TP53-EphA-2-CAR-DC + anti-PD-1 antibody/anti-CTLA4 antibody | Recruiting |
NCT05631899 | Local Advanced/Metastatic Solid Tumors | Phase â… | KRAS-EphA-2-CAR-DC + anti-PD-1 antibody/anti-CTLA4 antibody | Recruiting |
NCT04201873 | Recurrent Glioblastoma | Phase â… | ATL-DC vaccine + Pembrolizumab | Recruiting |
NCT02070406 | Unspecified Adult Solid Tumor, Protocol Specific | Phase â… | DC vaccine + gene-modified T-cells + Ipilimumab | Terminated |
NCT03546426 | PD-L1 Negative Advanced Mesothelioma | Phase â… | Autologous DC vaccine + Pembrolizumab | Active, not recruiting |
NCT05457959 | Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase â… | Peptide-pulsed DC vaccine + Nivolumab + Ipilimumab | Withdrawn |
NCT05765084 | Malignant Pleural Mesothelioma | Phase â… /â…¡ | WT1/DC vaccine + Atezolizumab | Recruiting |
NCT04487756 | Extensive-stage SCLC | Phase â… /â…¡ | Autologous DC vaccine + Atezolizumab | Active, not recruiting |
NCT04888611 | Recurrent Glioblastoma | Phase â…¡ | GSC-DCV + Camrelizumab | Unknown |
NCT03782064 | Multiple Myeloma | Phase â…¡ | DC/MM Fusion vaccine (DC/MM vaccine) + Nivolumab | Terminated |
NCT06751849 | Advanced NSCLC | Phase â…¡ | DC vaccine + PD-1 Inhibitor + Radiotherapy | Recruiting |
NCT06522919 | mCRC | Phase â…¡ | DC vaccine + Pembrolizumab + FTD/TPI + Bevacizumab | Recruiting |
NCT04912765 | HCC and CRLM | Phase â…¡ | Neoantigen DC vaccine + Nivolumab | Recruiting |
NCT03406715 | Relapsed SCLC | Phase â…¡ | Ad.p53-DC + Nivolumab + Ipilimumab | Terminated |
NCT04348747 | TNBC or HER2+ BC or HR+ BC Brain Metastasis | Phase â…¡ | Anti-HER2/HER3 DC vaccine + Pembrolizumab | Recruiting |
